HUE061419T2 - ANTI-PSMA antitestek, PSMA-t és CD3-at megkötõ bispecifikus antigénkötõ molekulák és azok alkalmazása - Google Patents
ANTI-PSMA antitestek, PSMA-t és CD3-at megkötõ bispecifikus antigénkötõ molekulák és azok alkalmazásaInfo
- Publication number
- HUE061419T2 HUE061419T2 HUE16748023A HUE16748023A HUE061419T2 HU E061419 T2 HUE061419 T2 HU E061419T2 HU E16748023 A HUE16748023 A HU E16748023A HU E16748023 A HUE16748023 A HU E16748023A HU E061419 T2 HUE061419 T2 HU E061419T2
- Authority
- HU
- Hungary
- Prior art keywords
- psma
- binding molecules
- bispecific antigen
- bind
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199823P | 2015-07-31 | 2015-07-31 | |
| US201562222590P | 2015-09-23 | 2015-09-23 | |
| US201662351823P | 2016-06-17 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE061419T2 true HUE061419T2 (hu) | 2023-06-28 |
Family
ID=56610023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16748023A HUE061419T2 (hu) | 2015-07-31 | 2016-07-29 | ANTI-PSMA antitestek, PSMA-t és CD3-at megkötõ bispecifikus antigénkötõ molekulák és azok alkalmazása |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10179819B2 (pl) |
| EP (2) | EP3328888B1 (pl) |
| JP (2) | JP6975707B2 (pl) |
| KR (1) | KR20180042272A (pl) |
| CN (1) | CN108137700B (pl) |
| AR (1) | AR106570A1 (pl) |
| AU (1) | AU2016302928B2 (pl) |
| CA (1) | CA2994245A1 (pl) |
| DK (1) | DK3328888T3 (pl) |
| EA (1) | EA038603B1 (pl) |
| ES (1) | ES2935120T3 (pl) |
| FI (1) | FI3328888T3 (pl) |
| HK (1) | HK1255971A1 (pl) |
| HR (1) | HRP20230237T1 (pl) |
| HU (1) | HUE061419T2 (pl) |
| JO (1) | JOP20160154B1 (pl) |
| LT (1) | LT3328888T (pl) |
| MD (1) | MD3328888T2 (pl) |
| PL (1) | PL3328888T3 (pl) |
| PT (1) | PT3328888T (pl) |
| RS (1) | RS63991B1 (pl) |
| SI (1) | SI3328888T1 (pl) |
| TW (1) | TWI728990B (pl) |
| WO (1) | WO2017023761A1 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105051069B (zh) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| BR112017011092A2 (pt) | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| ES2846748T3 (es) | 2015-03-30 | 2021-07-29 | Regeneron Pharma | Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma |
| EP4129327A1 (en) | 2015-08-28 | 2023-02-08 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
| TWI783914B (zh) * | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗ｃｄ３雙特異性抗體及其用途 |
| BR112018070948A2 (pt) | 2016-04-13 | 2019-01-29 | Orimabs Ltd | anticorpos anti-psma e utilização dos mesmos |
| MA47325A (fr) | 2017-01-20 | 2019-11-27 | Juno Therapeutics Gmbh | Conjugués de surface cellulaire et compositions cellulaires et méthodes associées |
| CA3056261A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| KR102651965B1 (ko) * | 2017-06-05 | 2024-03-28 | 누맙 세러퓨틱스 아게 | 신규 항 cd3 항체 |
| CA3076632A1 (en) * | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
| JOP20200303A1 (ar) * | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | عوامل ربط psma واستخداماتها |
| AU2019290198A1 (en) * | 2018-06-21 | 2021-01-14 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof |
| KR20210054528A (ko) | 2018-08-31 | 2021-05-13 | 리제너론 파아마슈티컬스, 인크. | Cd3/c20 이중특이적 항체에 대한 사이토카인 방출 증후군을 경감시키는 투약 전략 |
| SG11202103628PA (en) | 2018-10-31 | 2021-05-28 | Regeneron Pharma | Method and system of identifying and quantifying a protein |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| JP2022530301A (ja) | 2019-02-22 | 2022-06-29 | 武▲漢▼友芝友生物制▲薬▼有限公司 | Ｃｄ３抗原結合性断片及びその使用 |
| EP3947440A1 (en) * | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for generating avid-binding multispecific antibodies |
| CA3136892A1 (en) * | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Methods of treating renal cancer with an anti- psma/cd3 antibody |
| BR112021020532A2 (pt) * | 2019-04-19 | 2022-03-15 | Janssen Biotech Inc | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 |
| CA3140816A1 (en) | 2019-06-14 | 2020-12-17 | Nathan Trinklein | Multispecific heavy chain antibodies binding to cd22 and cd3 |
| JP2022537019A (ja) * | 2019-06-21 | 2022-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| BR112021026663A2 (pt) * | 2019-07-02 | 2022-04-12 | Telix Int Pty Ltd | Anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatal |
| CN114630907A (zh) * | 2019-07-26 | 2022-06-14 | 艾夏卡法国有限公司 | 用于细胞靶向和标记的抗cd3核酸适配体 |
| JP2022547081A (ja) * | 2019-09-06 | 2022-11-10 | シンフォジェン・アクシェセルスケープ | 抗ｃｄ７３抗体 |
| PE20221574A1 (es) * | 2020-01-06 | 2022-10-06 | Cytomx Therapeutics Inc | Compuestos relacionados con auristatina, compuestos conjugados de auristatina y metodos de uso de ellos |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN111303288B (zh) * | 2020-03-04 | 2020-12-25 | 和铂医药(苏州)有限公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| WO2021231976A1 (en) * | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| TW202237654A (zh) | 2020-12-09 | 2022-10-01 | 美商詹努克斯治療有限公司 | 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法 |
| EP4284512A1 (en) | 2021-01-28 | 2023-12-06 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| MX2023008909A (es) * | 2021-01-28 | 2023-10-23 | Janssen Biotech Inc | Proteínas de unión a psma y usos de estas. |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| US20240209115A1 (en) | 2021-04-29 | 2024-06-27 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
| US20230265218A1 (en) | 2022-02-23 | 2023-08-24 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| WO2023183231A1 (en) | 2022-03-21 | 2023-09-28 | Amgen Inc. | Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023224912A1 (en) | 2022-05-16 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2024035953A2 (en) * | 2022-08-11 | 2024-02-15 | Adicet Therapeutics, Inc. | Affinity binding entities directed to psma and methods of use thereof |
| WO2024118940A1 (en) * | 2022-12-01 | 2024-06-06 | Twist Bioscience Corporation | Anti-psma antibodies and uses thereof |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017981A (en) | 1911-05-29 | 1912-02-20 | Auguste Arsene Lemetre | Electroplating with zinc. |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| CA2250141C (en) | 1996-03-25 | 2008-07-29 | Pacific Northwest Cancer Foundation | Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| JP4619651B2 (ja) | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| EP3184539A3 (en) | 2001-10-23 | 2017-09-13 | PSMA Development Company L.L.C. | Psma antibodies |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| CN101124249B (zh) | 2005-02-18 | 2011-06-29 | 米德列斯公司 | 抗前列腺特异性膜抗原（psma）的人单克隆抗体 |
| DK2374818T3 (da) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| ME02485B (me) | 2008-10-01 | 2017-02-20 | Amgen Res Munich Gmbh | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću |
| KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| HUE045591T2 (hu) | 2010-02-08 | 2019-12-30 | Regeneron Pharma | Közönséges könnyûláncú egér |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| CN104136769B (zh) * | 2012-03-30 | 2016-09-21 | 川崎重工业株式会社 | 水力发电装置 |
| BR112014025830A8 (pt) * | 2012-04-20 | 2017-10-10 | Emergent Product Dev Seattle | Polipeptídeos de ligação ao cd3 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
-
2016
- 2016-07-25 JO JOP/2016/0154A patent/JOP20160154B1/ar active
- 2016-07-28 TW TW105123831A patent/TWI728990B/zh active
- 2016-07-29 HR HRP20230237TT patent/HRP20230237T1/hr unknown
- 2016-07-29 KR KR1020187005964A patent/KR20180042272A/ko not_active Application Discontinuation
- 2016-07-29 US US15/223,434 patent/US10179819B2/en active Active
- 2016-07-29 PT PT167480235T patent/PT3328888T/pt unknown
- 2016-07-29 CN CN201680058001.9A patent/CN108137700B/zh active Active
- 2016-07-29 ES ES16748023T patent/ES2935120T3/es active Active
- 2016-07-29 JP JP2018504829A patent/JP6975707B2/ja active Active
- 2016-07-29 DK DK16748023.5T patent/DK3328888T3/da active
- 2016-07-29 WO PCT/US2016/044732 patent/WO2017023761A1/en active Application Filing
- 2016-07-29 AU AU2016302928A patent/AU2016302928B2/en active Active
- 2016-07-29 CA CA2994245A patent/CA2994245A1/en active Pending
- 2016-07-29 EA EA201890368A patent/EA038603B1/ru unknown
- 2016-07-29 RS RS20230150A patent/RS63991B1/sr unknown
- 2016-07-29 EP EP16748023.5A patent/EP3328888B1/en active Active
- 2016-07-29 FI FIEP16748023.5T patent/FI3328888T3/fi active
- 2016-07-29 PL PL16748023.5T patent/PL3328888T3/pl unknown
- 2016-07-29 MD MDE20180558T patent/MD3328888T2/ro unknown
- 2016-07-29 SI SI201631655T patent/SI3328888T1/sl unknown
- 2016-07-29 EP EP22203815.0A patent/EP4183805A1/en active Pending
- 2016-07-29 LT LTEPPCT/US2016/044732T patent/LT3328888T/lt unknown
- 2016-07-29 HU HUE16748023A patent/HUE061419T2/hu unknown
- 2016-08-01 AR ARP160102342A patent/AR106570A1/es unknown
-
2018
- 2018-11-23 HK HK18115045.3A patent/HK1255971A1/zh unknown
- 2018-11-30 US US16/205,917 patent/US11155633B2/en active Active
-
2021
- 2021-09-16 US US17/476,856 patent/US20210403595A1/en active Pending
- 2021-11-05 JP JP2021180839A patent/JP7271637B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255971A1 (zh) | 抗psma抗體、結合psma及cd3的雙特異性抗原結合分子及其用途 | |
| HUS2300011I1 (hu) | Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai | |
| IL289946A (en) | Bispecific antibodies against cd3 and cd20 | |
| ZA201901066B (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| IL259082A (en) | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof | |
| HK1249523A1 (zh) | 一種結合和egfrviii和cd3的雙特異性抗體構建物 | |
| HK1248250A1 (zh) | 連接中皮素和cd3的雙特異性抗體構建體 | |
| HK1249525A1 (zh) | 一種結合dll3和cd3的雙特異性抗體構建 | |
| ZA201701341B (en) | Bispecific her2 and cd3 binding molecules |